It’s that time of the year again already… the ASCO GU Preview series! The good news is that there is a bumper crop of intriguing data to discuss this year.
With the ASCO embargo on the GU Symposium in San Francisco lifting at 5pm, there’s a lot to consider not merely in terms of the data itself, but more importantly, in terms of a broader context and the landscapes involved in prostate, renal and urothelial cancers.
Here we take a look at some of the key highlights to watch out for and what they mean in context.
A separate post on the phase 3 PROSPER data for enzalutamide in prostate cancer with a discussion on the ongoing enzalutamide/abiraterone/ADT/chemotherapy debate as part of the GU18 coverage is also available.